| 國立成功大學 |
2024-11 |
Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 tri
|
Boku;Narikazu;Omori;Takeshi;Shitara;Kohei;Sakuramoto;Shinichi;Yamaguchi;Kensei;Kato;Ken;Kadowaki;Shigenori;Tsuji;Kunihiro;Ryu;Min-Hee;Oh;Do-Youn;Oh;Cheul, Sang;Rha;Young, Sun;Lee;Keun-Wook;Chung;Ik-Joo;Sym;Jin, Sun;Chen;Li-Tzong;Chen;Jen-Shi;Bai;Li-Yuan;Nakada;Takashi;Hagihara;Shunsuke;Makino;Reina;Nishiyama;Eiji;Kang;Yoon-Koo |
| 國立成功大學 |
2024-08 |
Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, pl
|
Kang;Yoon-Koo;Terashima;Masanori;Kim;Young-Woo;Boku;Narikazu;Chung;Cheol, Hyun;Chen;Jen-Shi;Ji;Jiafu;Yeh;Ta-Sen;Chen;Li-Tzong;Ryu;Min-Hee;Kim;Gwang, Jong;Omori;Takeshi;Rha;Young, Sun;Kim;Yong, Tae;Ryu;Won, Keun;Sakuramoto;Shinichi;Nishida;Yasunori;Fukushima;Norimasa;Yamada;Takanobu;Bai;Li-Yuan;Hirashima;Yoshinori;Hagihara;Shunsuke;Nakada;Takashi;Sasako;Mitsuru |
| 國立成功大學 |
2024-08 |
Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1) : updated overall survival from a randomised phase 3 study
|
Oh;Do-Youn;He;Ruth, Aiwu;Bouattour;Mohamed;Okusaka;Takuji;Qin;Shukui;Chen;Li-Tzong;Kitano;Masayuki;Lee;Choong-kun;Kim;Won, Jin;Chen;-Huang, Ming;Suksombooncharoen;Thatthan;Ikeda;Masafumi;Lee;Ah, Myung;Chen;Jen-Shi;Potemski;Piotr;Burris;Howard, A.;Ostwal;Vikas;Tanasanvimon;Suebpong;Morizane;Chigusa;Zaucha;Renata, E.;Mcnamara;Mairead, G.;Avallone;Antonio;Cundom;Juan, E.;Breder;Valeriy;Tan;Benjamin;Shimizu;Satoshi;Tougeron;David;Evesque;Ludovic;Petrova;Mila;Zhen;David, B.;Gillmore;Roopinder;Gupta;Govinda, Vineet;Dayyani;Farshid;Park;Oh, Joon;Jr, Buchschacher;Gary, L.;Rey;Felipe;Kim;Hyosung;Wang;Julie;Morgan;Claire;Rokutanda;Nana;Zotkiewicz;Magdalena;Vogel;Arndt;Valle;Juan, W. |
| 國立成功大學 |
2024-06 |
Systemic treatments in pancreatic cancer: Taiwan pancreas society recommendation
|
Su;Yung-Yeh;Chiang;Nai-Jung;Chiu;Tai-Jan;Huang;Chien-Jui;Hsu;Shao-Jung;Lin;Hsin-Chen;Yang;Shih-Hung;Yang;Youngsen;Chou;Wen-Chi;Chen;Yen-Yang;Bai;Li-Yuan;Li;Chung-Pin;Chen;Jen-Shi |
| 國立成功大學 |
2024-05 |
Impact of previous S-1 treatment on efficacy of liposomal irinotecan plus 5-fluorouracil and leucovorin in patients with metastatic pancreatic cancer
|
Tang;Cheng-Yu;Yang;Shih-Hung;Li;Chung-Pin;Su;Yung-Yeh;Chiu;Sz-Chi;Bai;Li-Yuan;Shan;Yan-Shen;Chen;Li-Tzong;Chuang;Shih-Chang;Chan;De-Chuan;Yen;Chia-Jui;Peng;Cheng-Ming;Chiu;Tai-Jan;Chen;Yen-Yang;Chen;Jen-Shi;Chiang;Nai-Jung;Chou;Wen-Chi |
| 國立成功大學 |
2023-09-1 |
Carbohydrate Antigen 19-9 Response to Initial Adjuvant Chemotherapy Predicts Survival and Failure Pattern of Resected Pancreatic Adenocarcinoma but Not Which Patients Are Suited for Additional Adjuvant Chemoradiation Therapy: From a Prospective Randomized
|
Chiu;Yen-Feng;Liu;Tsang-Wu;Shan;Yan-Shen;Chen;Jen-Shi;Li;Chung-Pin;Ho;Ching-Liang;Hsieh;Ruey-Kuen;Hwang;Tsann-Long;Chen;Li-Tzong;Chang;Hui-Ju |
| 國立成功大學 |
2023-08 |
The impact of preoperative waiting time in Stage II-III gastric or gastroesophageal junction cancer: A population-based cohort study
|
Yen;Chih-Chieh;Yang;Yi-Hsin;Ku;Hsiu-Ying;Hu;Huang-Ming;Lo;Su-Shun;Chang;Hung-Chi;Chao;Yee;Chen;Jen-Shi;Wang;Hsiu-Po;Wang;Tsang-En;Bai;Li-Yuan;Wu;Ming-Shiang;Yen;Chia-Jui;Chen;Li-Tzong;Shan;Yan-Shen |
| 國立成功大學 |
2023-02 |
Real-World Data Validation of NAPOLI-1 Nomogram for the Prediction of Overall Survival in Metastatic Pancreatic Cancer
|
Su;Yung-Yeh;Chiang;Nai-Jung;Yang;Yi-Hsin;Yen;Chia-Jui;Bai;Li-Yuan;Chiu;Chang-Fang;Chuang;Shih-Chang;Yang;Shih-Hung;Chou;Wen-Chi;Chen;Jen-Shi;Chiu;Tai-Jan;Chen;Yen-Yang;Chan;De-Chuan;Peng;Cheng-Ming;Chiu;Sz-Chi;Li;Chung-Pin;Shan;Yan-Shen;Chen;Li-Tzong |
| 國立成功大學 |
2022-06-22 |
Dosing Pattern and Early Cumulative Dose of Liposomal Irinotecan in Metastatic Pancreatic Cancer: A Real-World Multicenter Study
|
Su;Yung-Yeh;Chiang;Nai-Jung;Li;Chung-Pin;Yen;Chia-Jui;Yang;Shih-Hung;Chou;Wen-Chi;Chen;Jen-Shi;Chiu;Tai-Jan;Chen;Yen-Yang;Chuang;Shih-Chang;Bai;Li-Yuan;Chiu;Chang-Fang;Peng;Cheng-Ming;Chan;De-Chuan;Chiu;Sz-Chi;Yang;Yi-Hsin;Shan;Yan-Shen;Chen;Li-Tzong |
| 國立成功大學 |
2022 |
Original Article The impact of spleen volume on the survival of metastatic pancreatic adenocarcinoma patients receiving nanoliposomal irinotecan
|
Yang;Shih-Hung;Chiang;Nai-Jung;Chiu;Sz-Chi;Chou;Wen-Chi;Bai;Li-Yuan;Li;Chung-Pin;Su;Yung-Yeh;Chiu;Tai-Jan;Chuang;Shih-Chang;Peng;Cheng-Ming;Chan;De-Chuan;Chen;Jen-Shi;Yen;Chia-Jui;Chen;Yen-Yang;Chiu;Chang-Fang;Chen;Li-Tzong;Shan;Yan-Shen |
